Our UHN programs and services are among the most advanced in the world. We have grouped our physicians, staff, services and resources into 10 medical programs to meet the needs of our patients and help us make the most of our resources.
University Health Network is a health care and medical research organization in Toronto, Ontario, Canada. The scope of research and complexity of cases at UHN has made us a national and international source for discovery, education and patient care.
Our 10 medical programs are spread across eight hospital sites – Princess Margaret, Toronto General, Toronto Rehab’s five sites, Toronto Western – as well as our education programs through the Michener Institute of Education at UHN. Learn more about the services, programs and amenities offered at each location.
Maps & Directions
Find out how to get to and around our nine locations — floor plans, parking, public transit, accessibility services, and shuttle information.
Ways You Can Help
Being touched by illness affects us in different ways. Many people want to give back to the community and help others. At UHN, we welcome your contribution and offer different ways you can help so you can find one that suits you.
The Newsroom is the source for media looking for information about UHN or trying to connect with one of our experts for an interview. It’s also the place to find UHN media policies and catch up on our news stories, videos, media releases, podcasts and more.
Toronto (May 22, 2011) - Researchers at the Peter Munk Cardiac Centre discovered a protein switch which can trigger a cascade of events leading to heart failure, pointing to a new direction for drug development.
"Our research suggests that PINK1 is an important switch that sets off a cascade of events affecting heart cell metabolism," says Dr. Phyllis Billia, principal author, clinician-scientist and heart failure specialist at the Peter Munk Cardiac Centre. "This could be one of the inciting events in the development of heart failure."
The findings, published today in Proceedings of the National Academy of Sciences, show that the absence of a certain protein, PINK1, causes heart cells to produce less energy. This lack of energy causes some heart cells to die, forcing the remaining cells to work harder to keep the heart going. In response to this stress, the heart muscle cells thicken, a condition known as hypertrophy.
Heart failure is the most common cause of hospitalization in North American adults, and over 50,000 are treated for advanced heart failure annually. Transplantation is the only long-term treatment for end-stage heart failure patients and the long wait times for a matching donor organ make it necessary to find other alternatives.
"Heart Failure remains a silent epidemic in North America, except for those who suffer from this devastating disease. Current therapies, while effective, only target the symptoms of heart failure," says Dr. Vivek Rao, co-author of the study and Surgical Director of the Heart Transplant Program at the Peter Munk Cardiac Centre. "The discovery of PINK-1's role in the development of heart failure may lead to novel treatment to prevent heart failure in those at risk. This discovery represents a novel and as yet, untapped mechanism to fight the battle against heart failure."
In the lab, researchers "knocked-out" or genetically removed the PINK1 gene in mice and studied their heart cells under the microscope. They found that although the hearts initially develop normally, they begin to fail after two months, suggesting that PINK1 isn't required for organ development; rather it is crucial for protecting against heart failure.
Until now, research into the PINK1 gene has focused on its links to early-onset Parkinson's disease and certain cancers including esophageal and endometrial. This is the first study to establish its connection to heart disease.
While more research is required to develop potential clinical treatments, this discovery represents a new way of thinking about the involvement of certain proteins in the progression of heart failure.
"We need to learn more about PINK1 and the other proteins it interacts with at the sub-cellular level," says Dr. Billia. "But if we've identified the inciting event that causes the chain of events leading to failure, research and drug development strategies should be focused in this new area of science."
Dr. Billia conducted this research in the cell metabolism laboratory of Dr. Tak Mak, Director of the Campbell Family Institute for Breast Cancer Research at Princess Margaret Hospital. Dr. Mak is internationally renowned for his important breakthroughs in immunology and our understanding of cancer at the molecular level.
The research published today was financially supported by grants from the Canadian Institutes of Health Research.
The Peter Munk Cardiac Centre is the premier cardiac centre in Canada. Since it opened in 1997, the Centre has saved and improved the lives of cardiac and vascular patients from around the world. Each year, approximately 17,000 patients receive innovative and compassionate care from multidisciplinary teams in the Peter Munk Cardiac Centre, and the Centre trains more cardiologists, cardiovascular surgeons and vascular surgeons than any hospital in Canada. The Centre is based at the Toronto General Hospital and the Toronto Western Hospital - members of University Health Network, which also includes Princess Margaret Hospital. All three sites are research hospitals affiliated with the University of Toronto. For more information please visit www.petermunkcardiaccentre.ca.
Phone: 416 340 4636